BR112022007128A2 - Ligação de proteínas nkg2d, cd16 e flt3 - Google Patents

Ligação de proteínas nkg2d, cd16 e flt3

Info

Publication number
BR112022007128A2
BR112022007128A2 BR112022007128A BR112022007128A BR112022007128A2 BR 112022007128 A2 BR112022007128 A2 BR 112022007128A2 BR 112022007128 A BR112022007128 A BR 112022007128A BR 112022007128 A BR112022007128 A BR 112022007128A BR 112022007128 A2 BR112022007128 A2 BR 112022007128A2
Authority
BR
Brazil
Prior art keywords
nkg2d
protein binding
flt3 protein
flt3
proteins
Prior art date
Application number
BR112022007128A
Other languages
English (en)
Inventor
Baruah Hemanta
P Chang Gregory
F Cheung Ann
Grinberg Asya
Sean Juo Zong
J Mcquade Thomas
Fallon Daniel
Haney William
O'neil Steven
Wei Ronnie
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of BR112022007128A2 publication Critical patent/BR112022007128A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

LIGAÇÃO DE PROTEÍNAS NKG2D, CD16 E FLT3. A presente invenção refere-se a proteínas de ligação multiespecíficas que se ligam ao receptor NKG2D, CD16 e FLT3, bem como composições farmacêuticas e métodos terapêuticos úteis para o tratamento de doenças autoimunes ou câncer.
BR112022007128A 2019-10-15 2020-10-14 Ligação de proteínas nkg2d, cd16 e flt3 BR112022007128A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962915123P 2019-10-15 2019-10-15
PCT/US2020/055497 WO2021076564A1 (en) 2019-10-15 2020-10-14 Proteins binding nkg2d, cd16 and flt3

Publications (1)

Publication Number Publication Date
BR112022007128A2 true BR112022007128A2 (pt) 2022-07-05

Family

ID=75538862

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007128A BR112022007128A2 (pt) 2019-10-15 2020-10-14 Ligação de proteínas nkg2d, cd16 e flt3

Country Status (16)

Country Link
US (1) US20240117054A1 (pt)
EP (1) EP4045538A1 (pt)
JP (1) JP2022551969A (pt)
KR (1) KR20220083770A (pt)
CN (1) CN115298217A (pt)
AR (1) AR120223A1 (pt)
AU (1) AU2020368163A1 (pt)
BR (1) BR112022007128A2 (pt)
CA (1) CA3153858A1 (pt)
CL (1) CL2022000928A1 (pt)
CO (1) CO2022004757A2 (pt)
IL (1) IL292261A (pt)
MX (1) MX2022004430A (pt)
PE (1) PE20221316A1 (pt)
TW (1) TW202128759A (pt)
WO (1) WO2021076564A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
CN115925984A (zh) * 2021-08-24 2023-04-07 广东东阳光药业有限公司 Gdf15融合蛋白及其用途
WO2023056252A1 (en) * 2021-09-29 2023-04-06 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and baff-r
WO2023107956A1 (en) * 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
CA2992539A1 (en) * 2015-07-16 2017-01-19 Cellerant Therapeutics, Inc. Cysteine-substituted immunoglobulins
US20200165344A1 (en) * 2017-07-31 2020-05-28 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and flt3

Also Published As

Publication number Publication date
TW202128759A (zh) 2021-08-01
EP4045538A1 (en) 2022-08-24
US20240117054A1 (en) 2024-04-11
PE20221316A1 (es) 2022-09-07
IL292261A (en) 2022-06-01
AU2020368163A1 (en) 2022-04-28
CN115298217A (zh) 2022-11-04
WO2021076564A1 (en) 2021-04-22
KR20220083770A (ko) 2022-06-20
MX2022004430A (es) 2022-07-19
CL2022000928A1 (es) 2022-10-28
CO2022004757A2 (es) 2022-09-30
AR120223A1 (es) 2022-02-02
JP2022551969A (ja) 2022-12-14
CA3153858A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
BR112022007128A2 (pt) Ligação de proteínas nkg2d, cd16 e flt3
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
BR112017016336A2 (pt) proteínas de ligação icos agonistas?
AR105444A1 (es) Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
BR112018010084A2 (pt) ligantes de pd1 e/ou lag3
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112017025529A2 (pt) agentes de ligação ao tigit e usos destes
MX2019002867A (es) Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
BR112022021884A2 (pt) Proteínas que se ligam a nkg2d, cd16 e clec12a
EP3882270A3 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
BR112018068678A2 (pt) anticorpos anti-mica
MX2019009848A (es) Proteínas que se unen a her2, nkg2d y cd16.
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
MX2020002626A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumores.
CL2023002108A1 (es) Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.
CO2020001981A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
BR112016023011A2 (pt) tratamento de câncer gástrico
PH12019500342A1 (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6